Recent editorials in the New York Times and Los Angeles Times called into question the current use of lethal injection in executions, in light of the decision by the sole U.S. manufacturer of a key drug used by almost all states to stop its production. Hospira Inc. was the only U.S. producer of sodium thiopental, the main anesthetic used in lethal injections, but the company said international concerns about the death penalty prompted its halt. The shortage of the drug caused some states to seek it overseas. The New York Times cited a litany of problems with the batches of the drug used in recent executions in Arizona and Georgia. "Even with judicial blessing, the conduct of executions in this country is a shambles. In Arizona and Georgia, the sodium thiopental used in executions has possibly been ineffective and almost certainly been illegal. It came from Dream Pharma, an unlicensed British supplier, run from a driving school. The batches carried a date of 2006. They were likely made by a company in Austria that went out of business. The drug is said to be effective for only a year. As a foreign-made drug without approval by the Food and Drug Administration, it is prohibited by federal statute." In a similar editorial, the Los Angeles Times noted, "If this were just a supply problem, it might be comparatively easy to solve. But lethal injection, considered the most 'humane' way to execute criminals, comes with a host of other ethical, regulatory and legal challenges. Medical associations refuse to condone physician participation in executions, increasing the danger of botched procedures. The Food and Drug Administration wants nothing to do with lethal-injection drugs, refusing to verify the effectiveness of imports but allowing states to purchase them. Thus there is no way of knowing whether the drugs are producing the 'painless' death they promise, or a torturous death forbidden by the Constitution." Read the full editorials below.